To Compare The Effects Of Two Doses Of Vandetanib In Patients With Advanced Medullary Thyroid Cancer
Trial · NCT01496313
Results by group38
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 38
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Overall Response Rate (ORR) for Vandetanib 150 and 300mg With Responses Determined by the Investigator | Vandetanib 150 mg | 0.20 | 95% Confidence Interval 0.105 to 0.348 | Proportion of participants | |
| Overall Response Rate (ORR) for Vandetanib 150 and 300mg With Responses Determined by the Investigator | Vandetanib 300 mg | 0.29 | 95% Confidence Interval 0.176 to 0.445 | Proportion of participants | |
| Best Objective Response | Vandetanib 150 mg | Complete response | 0 | Participants | |
| Best Objective Response | Vandetanib 300 mg | Complete response | 1 | Participants | |
| Best Objective Response | Vandetanib 150 mg | Partial response | 8 | Participants | |
| Best Objective Response | Vandetanib 300 mg | Partial response | 11 | Participants | |
| Best Objective Response | Vandetanib 150 mg | Stable disease | 21 | Participants | |
| Best Objective Response | Vandetanib 300 mg | Stable disease | 23 | Participants | |
| Best Objective Response | Vandetanib 150 mg | Progressive disease | 9 | Participants | |
| Best Objective Response | Vandetanib 300 mg | Progressive disease | 2 | Participants | |
| Best Objective Response | Vandetanib 150 mg | Non-evaluable | 2 | Participants | |
| Best Objective Response | Vandetanib 300 mg | Non-evaluable | 4 | Participants | |
| Duration of Objective Response (RECIST 1.1) by Treatment Arm | Vandetanib 150 mg | 9.8 | 95% Confidence Interval 2.8 to 11.2 | Months | |
| Duration of Objective Response (RECIST 1.1) by Treatment Arm | Vandetanib 300 mg | 8.4 | 95% Confidence Interval 3.0 to 11.2 | Months | |
| Time to Objective Response (RECIST 1.1) by Treatment Arm | Vandetanib 150 mg | 4.2 | 95% Confidence Interval 2.8 to 11.2 | Months | |
| Time to Objective Response (RECIST 1.1) by Treatment Arm | Vandetanib 300 mg | 4.4 | 95% Confidence Interval 2.8 to 11.1 | Months | |
| Percentage Change From Baseline in Target Lesion Size (RECIST 1.1) by Treatment Arm | Vandetanib 150 mg | Week 12 | -3.8 | Standard Deviation 29.24 | % change |
| Percentage Change From Baseline in Target Lesion Size (RECIST 1.1) by Treatment Arm | Vandetanib 300 mg | Week 12 | -17.5 | Standard Deviation 18.24 | % change |
| Percentage Change From Baseline in Target Lesion Size (RECIST 1.1) by Treatment Arm | Vandetanib 150 mg | Week 24 | -13.0 | Standard Deviation 19.51 | % change |
| Percentage Change From Baseline in Target Lesion Size (RECIST 1.1) by Treatment Arm | Vandetanib 300 mg | Week 24 | -24.9 | Standard Deviation 22.11 | % change |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01496313/results